Los Gatos, California – December 1, 2025 – Venova Medical, a privately held company developing a next generation technology for the creation of percutaneous arteriovenous fistulas (pAVF) for hemodialysis access, announced today the publication of first-in-human...
Rishi Razdan, MD, Medical Director of Azura Vascular Care Jacksonville in Jacksonville, Florida, presented mid-term results from the Venova Medical sponsored VENOS-2 study during the 2025 Controversies in Dialysis Access (CiDA) meeting held in Boston, Massachusetts....
(Los Gatos, California) – Venova Medical, Inc. (Venova Medical), a privately held company developing a next generation technology for the creation of percutaneous arteriovenous fistulas (pAVF) for hemodialysis access today announced that it will present an oral...
Robert Shahverdyan, MD, from Hamburg, Germany presented one-year results from the VENOS-1 first-in-human study, which examined the VelocityTM Percutaneous Arteriovenous Fistula (pAVF) System during the recent Controversies in Dialysis Access (CiDA) meeting held in...
While currently available percutaneous arteriovenous fistula (pAVF) devices have demonstrated a high rate of technical procedural success, secondary interventions are often required to achieve fistula maturation with these devices. CLICK HERE to read an excellent...
During the recent Charing Cross (CX) International Symposium held in London, Robert Shahverdyan, MD detailed the challenges associated with the use of current endovascular arteriovenous fistula (endoAVF) devices and provided insights from his clinical experience with...
